08:00
09:10
Opening
Prof. Matthias D'HOOGHE
GHENT UNIVERSITY, Ghent, Belgium
Session 1
Session Chair
Prof. Christian STEVENS
UGENT, Ghent, Belgium
09:30
Heterocycles as Key Features of New Starting Points for Drug Discovery (PL01)
Dr Peter MEIER
NOVARTIS PHARMA AG, Basel, Switzerland
Peter Meier studied chemistry in Basel, Switzerland, to receive his diploma in 1994. He moved to Geneva to join the group of Prof. E. Peter Kündig to work on the development of new chiral auxiliaries and ligands for the asymmetric catalysis and received his PhD in 1999. From 1999 to 2001 he joined the group of Prof. Dale Boger at the Scripps Research Institute in La Jolla, working on the total synthesis of Rampolanin. He returned to Basel in 2001 to start his career within Novartis in the Combinatorial Chemistry Unit where he actively contributed to the transformations in this field, from technical development to library design, outsourcing of the production and library performance analysis what impacted numerous pipeline projects. In 2016 he joined the newly formed Hit Generation Sciences group at Novartis where he is currently involved in the application and further development of the DNA encoded library approach as well as compound optimization up to proof of concept studies in early drug discovery projects.
10:15
Development of Enzyme Inhibitors and Multi-target-directed Ligands for Treating Neurodegenerative Diseases (IL01)
Prof. Stanislav GOBEC
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
TITLE AND POSITION
Professor of Pharmaceutical Chemistry, Head of Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Slovenia
RESEARCH INTEREST
Drug discovery, medicinal and pharmaceutical chemistry, in-silico drug design, virtual high-throughput screening, enzyme inhibitors, organic chemistry, molecular pharmacology
EDUCATION AND FORMER PROFESSIONAL EXPERIENCES
- 1994 M.Sc. in Pharmacy
- 1999 doctoral thesis in the field of Medicinal Chemistry
- From December 2010 on: Full Professor in the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana
- From. Oct. 2007 to Oct. 2011, Dean in the Faculty of Pharmacy, and member of the University of Ljubljana Senate
- From 2011- Head of Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Slovenia
10:45
Session 2
Session Chair
Prof. Till OPATZ
JOHANNES GUTENBERG-UNIVERSITY, Mainz, Germany
11:15
Silil-Prins Cyclization: Towards the Synthesis of Medium Sized Heterocycles (OC01)
Prof. Asuncion BARBERO
UNIVERSITY OF VALLADOLID, Valladolid, Spain
11:30
Chiral Piperidines from Pyridines: the Meta-Substitution Challenge in Asymmetric Hydrogenation (OC02)
Dr Paul ALSTERS
INNOSYN B.V., Geleen, The Netherlands
Paul Alsters obtained his Ph.D. at the University of Utrecht (The Netherlands) in 1992 with Prof. G. van Koten. He did postdoctoral work in the laboratory of R.O. Duthaler at Ciba-Geigy in Basel (Switzerland). He joined DSM in 1993, where he worked until April 2017 as a principal scientist within DSM Ahead. Since May 2017, he works at InnoSyn (www.innosyn.com) on the Brightlands campus in Geleen (The Netherlands), where he is principal scientist "Chemocatalysis". His main areas of interest are development of scalable break-through methods for new or existing products, and liquid-phase catalysis, with an emphasis on C-X or C-C coupling reactions and oxidation catalysis.
11:45
Expanding the Chemical Space of Chiral Trifunctional Building Blocks by Stereoselective Synthesis from Natural Terpenes (IL02)
Prof. Zsolt SZAKONYI
UNIVERSITY OF SZEGED, Szeged, Hungary
Zsolt Szakonyi (born 1969) received his Master's degree in Pharmacy in 1992. He undertook his PhD in synthetic organic chemistry in the group of Professor Ferenc Fülöp and held his Ph.D. Degree at the University of Szeged (Hungary) in 1998. He joined the research group of Prof. Norbert De Kimpe at the University of Ghent, Belgium in period of 1999-2000 as a postdoctoral Research Fellow by FWO. He became Associate Professor at the Institute of Pharmaceutical Chemistry, University of Szeged in 2007. His research interests center on stereoselective synthesis of monoterpene based bi- and tridentate building blocks, beta-amino acid derivetives, aminodiols and saturated 1,3-heterocycles with a special focus on homogeneous stereoselective catalysis.
12:15
Session 3
Session Chair
Prof. Fawaz ALDABBAGH
KINGSTON UNIVERSITY, London, United Kingdom
13:30
A Journey in Heteroaromatic Scaffolds as Protein Kinase Inhibitors (PL02)
Prof. Pascale MOREAU
UNIVERSITY OF CLERMONT AUVERGNE, Aubičre, France
Pascale Moreau obtained her Master Degree in biophysicochemistry and cellular and molecular biology under the supervision of Pr. Gérald Guillaumet and Pr. Michel Monsigny (Orléans, France). She received her Ph.D from the University of Orléans (France) in 1993 under the supervision of Pr. Gérard Coudert working on the synthesis and reactivity of 1,4-benzodioxine derivatives. She joined Pr. Victor A. Snieckus’s group at Waterloo University (Canada), as a postdoctoral fellow in 1994-1995, working on macrocycles synthesis and directed ortho-metalation. During a second post-doctoral position at Bristol-Myers-Squibb (Marne-la-Vallée, France) she focused on asymmetric synthesis. In 1996, she moved to Blaise Pascal University (Clermont-Ferrand, France) as a lecturer in the group of Pr. Michelle Prudhomme working on hemisynthesis of rebeccamycin derivatives. She was appointed as a Professor in 2007. Her current research is devoted to the development of new bioactive heteroaromatic compounds.
14:15
Bacterial Quinolones and Derivatives: New Drugs for Bad Bugs (IL03)
Dr Thomas BOTTCHER
UNIVERSITY OF KONSTANZ, Konstanz, Germany
Thomas Böttcher is leading an Emmy Noether research group in the field of Chemical Biology at the University of Konstanz. His research focusses on the chemistry of bacterial interactions and developing chemical tools to modulate bacterial behavior. Böttcher studied Chemistry and Biochemistry at the Ludwig Maximilian University (LMU) in Munich. In 2009 he finished his PhD in the group of Stephan Sieber and shortly thereafter cofounded the start-up company AVIRU for anti-infective drug development. Supported by a Leopoldina research fellowship, he moved in 2011 to Harvard Medical School for postdoctoral research with Jon Clardy and returned to Germany in 2014 to establish his independent research group in Konstanz. He received the 2018 Thieme Chemistry Journal award and is elected member of the German Young Aacademy (Die Junge Akademie) at the Berlin-Brandenburg Academy of Sciences and Humanities and the German National Academy of Sciences Leopoldina.
14:45
Hydrogen Peroxide and Hydrohalic Acid-Mediated Synthesis of Ring-Fused Benzimidazolequinone Anti-Cancer Agents (OC03)
Mr Darren CONBOY
KINGSTON UNIVERSITY LONDON, Kingston upon Thames, United Kingdom
Darren Conboy is currently in the final year of his PhD under the supervision of Prof Fawaz Aldabbagh at Kingston University London. Darren began his PhD in 2016 at the National University of Ireland Galway, where he also obtained First Class BSc (Hons) in Biopharmaceutical Chemistry (ranked first position in his class). A native of County Sligo, Ireland, Darren’s current research interests focus on the synthesis of heterocyclic small molecules with medicinal applications.
15:00
Session 4
Session Chair
Dr Bart ROMAN
GHENT UNIVERSITY, Ghent, Belgium
15:30
Thionations Using a P4S10-Pyridine Complex (OC04)
Ms Ngarita KINGI
VIRONOVA MEDICAL AB, Stockholm, Sweden
Ngarita Kingi obtained her M.Sc. in Chemistry from Södertörn University of Stockholm, Sweden. After her graduation in 2006 she joined Vironova Medical in Drug Development where she is presently working as a Senior Scientist. For more than 10 years she has worked with the discovery and development of small molecules for the treatment against viruses such as HIV, Herpes and Influenza. Currently she is evaluating the reagent P2S5·2C5H5N and its capabilities for thionating biologically active small molecules.
15:45
First Solid-Phase Strategy for the Total Synthesis of Fengycin Derivatives, a Class of Cyclic Lipodepsipeptides (OC05)
Dr Lidia FELIU
LIPPSO, UNIVERSITY OF GIRONA, Girona, Spain
Lidia Feliu completed her PhD degree at the University of Barcelona in 2000. During this period, her research was focused on the total synthesis in solution of marine pyridoacridine alkaloids with antitumor activity. In 2001, she obtained a two-year postdoctoral position at the University of Montpellier as Marie Curie Fellow. The postdoctoral research allowed her to start working on solid-phase peptide synthesis and combinatorial chemistry. In 2003, she got a Marie Curie Reintegration Grant and moved to the University of Girona. She joined the LIPPSO group as lecturer and became Associate Professor in 2008.
Her current research is focused on the design and the synthesis of peptides with biological activity, mainly antimicrobial or antitumor. She is interested in linear and cyclic peptides bearing natural or non-natural amino acids (D-, triazolyl and biaryl amino acids), depsipeptides, lipopeptides and peptide conjugates.
16:00
Design and Synthesis of New Nitrogen-Containing Heterocycles for the Treatment of Mechanical Allodynia (OC06)
Ms Alexia VISSEQ
INSTITUT DE CHIMIE DE CLERMONT FERRAND, AUBIERE, France
Alexia Visseq graduated in 2016 from the Ecole Nationale Supérieure de Chimie de Mulhouse (Mulhouse, France) as a chemical engineer and also obtained her M.Sc. in chemical synthesis from Haute Alsace University (Mulhouse, France). Since then, she is carrying out a Ph.D. in medicinal chemistry under the supervision of Professor Fabrice Anizon and Dr. Isabelle Thomas at Clermont Auvergne University at the Chemistry Institute of Clermont-Ferrand (Clermont-Ferrand, France). Her research interests focus on the synthesis of new selective protein kinase inhibitors for the treatment of mechanical allodynia.
16:15
18:00
Welcome Reception (Ghent City Hall)